- Home
- REBN vs EVAX Comparison
REBN vs EVAX Comparison
Compare REBN & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- EVAX
- Stock Information
- Founded
- REBN 2015
- EVAX 2008
- Country
- REBN United States
- EVAX Denmark
- Employees
- REBN N/A
- EVAX N/A
- Industry
- REBN Restaurants
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- REBN Consumer Discretionary
- EVAX Health Care
- Exchange
- REBN Nasdaq
- EVAX Nasdaq
- Market Cap
- REBN 15.3M
- EVAX 17.8M
- IPO Year
- REBN 2022
- EVAX 2021
- Fundamental
- Price
- REBN $2.42
- EVAX $6.29
- Analyst Decision
- REBN
- EVAX Strong Buy
- Analyst Count
- REBN 0
- EVAX 2
- Target Price
- REBN N/A
- EVAX $11.00
- AVG Volume (30 Days)
- REBN 77.7K
- EVAX 4.4M
- Earning Date
- REBN 11-18-2025
- EVAX 10-30-2025
- Dividend Yield
- REBN N/A
- EVAX N/A
- EPS Growth
- REBN N/A
- EVAX N/A
- EPS
- REBN N/A
- EVAX N/A
- Revenue
- REBN $6,565,623.00
- EVAX $3,176,000.00
- Revenue This Year
- REBN $335.98
- EVAX N/A
- Revenue Next Year
- REBN N/A
- EVAX $425.50
- P/E Ratio
- REBN N/A
- EVAX N/A
- Revenue Growth
- REBN 14.03
- EVAX 1042.45
- 52 Week Low
- REBN $1.03
- EVAX $1.20
- 52 Week High
- REBN $8.30
- EVAX $15.50
- Technical
- Relative Strength Index (RSI)
- REBN N/A
- EVAX 67.86
- Support Level
- REBN N/A
- EVAX $3.70
- Resistance Level
- REBN N/A
- EVAX $7.23
- Average True Range (ATR)
- REBN 0.00
- EVAX 0.66
- MACD
- REBN 0.00
- EVAX 0.27
- Stochastic Oscillator
- REBN 0.00
- EVAX 70.78
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.